Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 03 2020
Historique:
received: 15 09 2019
accepted: 27 02 2020
entrez: 12 3 2020
pubmed: 12 3 2020
medline: 24 11 2020
Statut: epublish

Résumé

The DNA damage response after kidney injury induces cell cycle arrest in renal tubular epithelial cells, resulting in the secretion of pro-fibrotic cytokines, thereby promoting interstitial fibrosis in a paracrine manner. Phosphorylation of ataxia-telangiectasia mutated (ATM) is the initial step in the DNA damage response and subsequent cell cycle arrest; however, the effects of ATM inhibition on the injured kidney have not been explored. Pharmacological ATM inhibition by KU55933 in cisplatin-treated mice did not ameliorate, but instead exacerbated cisplatin-induced DNA damage and tubular injury, thereby increasing mortality. Analysis of isolated tubular epithelia by FACS from bigenic SLC34a1-CreERt2; R26tdTomato proximal tubular-specific reporter mice revealed that KU55933 upregulated p53 and subsequent pro-apoptotic signaling in tubular epithelia of cisplatin-treated mice, leading to marked mitochondrial injury and apoptosis. In addition, KU55933 attenuated several DNA repair processes after cisplatin treatment, including single-strand DNA repair and Fanconi anemia pathways, suggesting that DNA repair after dual treatment of cisplatin and KU55933 was not sufficient to prevent the cisplatin-induced tubular injury. Our study suggested that ATM inhibition does not increase DNA repair after cisplatin-induced DNA damage and exacerbates tubular injury through the upregulation of p53-dependent pro-apoptotic signaling. Acute kidney injury must be carefully monitored when ATM inhibitors become available in clinical practice in the future.

Identifiants

pubmed: 32157166
doi: 10.1038/s41598-020-61456-7
pii: 10.1038/s41598-020-61456-7
pmc: PMC7064514
doi:

Substances chimiques

2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one 0
Antineoplastic Agents 0
Morpholines 0
Mutant Proteins 0
Pyrones 0
Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0
ATM protein, human EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4441

Références

Kidney Int. 2004 Jul;66(1):196-202
pubmed: 15200426
Oncotarget. 2017 Dec 11;9(4):4318-4337
pubmed: 29435105
Ther Adv Med Oncol. 2018 Jul 13;10:1758835918786658
pubmed: 30023007
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1527-32
pubmed: 24127583
Nat Rev Cancer. 2016 Jan;16(1):20-33
pubmed: 26678314
J Am Soc Nephrol. 2010 Jan;21(1):31-41
pubmed: 19892935
DNA Repair (Amst). 2016 Feb;38:84-93
pubmed: 26686657
J Biol Chem. 2010 Oct 22;285(43):33010-7
pubmed: 20709753
Kidney Int. 2013 Sep;84(3):457-67
pubmed: 23636171
Nat Med. 2010 May;16(5):535-43, 1p following 143
pubmed: 20436483
J Am Soc Nephrol. 2017 Mar;28(3):776-784
pubmed: 27624490
Clin Cancer Res. 2008 Mar 1;14(5):1291-5
pubmed: 18316546
Cancer Res. 2008 Sep 15;68(18):7466-74
pubmed: 18794134
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302
pubmed: 12370430
Nat Rev Mol Cell Biol. 2016 Jun;17(6):337-49
pubmed: 27145721
Cardiovasc Res. 2016 May 1;110(1):85-95
pubmed: 26862121
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
Biochim Biophys Acta. 2014 Jul;1842(7):1088-96
pubmed: 24726884
Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355
pubmed: 28984489
J Am Soc Nephrol. 2016 Mar;27(3):687-97
pubmed: 26519085
Cancer Res. 2004 Dec 15;64(24):9152-9
pubmed: 15604286
Clinics (Sao Paulo). 2018 Sep 06;73(suppl 1):e478s
pubmed: 30208165
Semin Nephrol. 2003 Sep;23(5):460-4
pubmed: 13680535
Pharmacol Ther. 2015 May;149:124-38
pubmed: 25512053
Cell. 2012 Jun 22;149(7):1536-48
pubmed: 22726440
Cell Cycle. 2014;13(22):3541-50
pubmed: 25483091
Nat Rev Nephrol. 2015 May;11(5):264-76
pubmed: 25643664
Nat Commun. 2017 Apr 24;8:15104
pubmed: 28436431
Nat Genet. 2003 Jan;33(1):80-4
pubmed: 12447371
J Clin Invest. 2019 Nov 1;129(11):4797-4816
pubmed: 31589169
J Am Soc Nephrol. 2001 May;12(5):900-8
pubmed: 11316848
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674655
Science. 1998 Sep 11;281(5383):1674-7
pubmed: 9733514
Nat Rev Genet. 2007 Oct;8(10):735-48
pubmed: 17768402
Annu Rev Biochem. 2015;84:711-38
pubmed: 25580527
BMC Cancer. 2017 Feb 20;17(1):144
pubmed: 28219368
Lancet. 2013 Jul 13;382(9887):158-69
pubmed: 23727165
Nature. 2013 Jan 17;493(7432):356-63
pubmed: 23325218
Kidney Int. 2012 Mar;81(5):442-8
pubmed: 22113526
J Am Soc Nephrol. 2014 Oct;25(10):2278-89
pubmed: 24700871
Kidney Int. 2012 Sep;82(5):516-24
pubmed: 22673882
Nat Protoc. 2006;1(1):23-9
pubmed: 17406208
Kidney Int. 2008 May;73(9):994-1007
pubmed: 18272962
Nat Commun. 2013;4:2308
pubmed: 23917356
J Am Soc Nephrol. 2001 May;12(5):983-92
pubmed: 11316857
J Am Soc Nephrol. 2009 Aug;20(8):1754-64
pubmed: 19470675
J Am Soc Nephrol. 2019 Jan;30(1):23-32
pubmed: 30510133
Nat Rev Mol Cell Biol. 2008 Oct;9(10):759-69
pubmed: 18813293
J Am Soc Nephrol. 2014 Dec;25(12):2707-16
pubmed: 24854277
Mol Cell Biol. 2004 Jul;24(14):6430-44
pubmed: 15226443
Mol Cancer Ther. 2013 Jun;12(6):959-67
pubmed: 23512991
Nat Rev Cancer. 2002 Aug;2(8):594-604
pubmed: 12154352
Nat Med. 2018 Jul;24(7):947-953
pubmed: 29892060
Cell. 2002 May 17;109(4):459-72
pubmed: 12086603
Biochem Pharmacol. 2005 Dec 5;70(12):1823-31
pubmed: 16242669

Auteurs

Masahiro Uehara (M)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Tetsuro Kusaba (T)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan. kusaba@koto.kpu-m.ac.jp.

Tomoharu Ida (T)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Kunihiro Nakai (K)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Tomohiro Nakata (T)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Aya Tomita (A)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Noriko Watanabe-Uehara (N)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Kisho Ikeda (K)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Takashi Kitani (T)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Noriyuki Yamashita (N)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Yuhei Kirita (Y)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Division of Nephrology, Washington University School of Medicine in St. Louis, St. Louis, USA.

Satoaki Matoba (S)

Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Benjamin D Humphreys (BD)

Division of Nephrology, Washington University School of Medicine in St. Louis, St. Louis, USA.

Keiichi Tamagaki (K)

Department of Nephrology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH